Table 3.
EC50 of hu3F8-scBA and 5F11-scBA T-cell cytotoxicity against various GD2(+) cancer cell lines. EC50 was determined by 51chromium release assay. Each scBA was serially diluted to create a killing curve, and was analyzed using Graphpad Prism 6, using a nonlinear fitting algorithm (log(agonist) vs. response-Variable slope (four parameters)). GD2 expression was measured by FACS with a standard curve of counting beads (BD QuantiBRITE).
| EC50 (pM) | EC50 (pM) | Folds of difference | |||
|---|---|---|---|---|---|
| Cancer type | Cell line (ATCC) | GD2 expression (MFI) | (5F11-scBA) | (Hu3F8-scBA) | (EC50) |
| Neuroblastoma | IMR-32 (CCL-127) | High | 136.5 | 0.0246 | 5,553 |
| Melanoma | M14 | High | 38.44 | 0.0104 | 3,707 |
| Neuroblastoma | LAN-1 | High | 104.3 | 0.0253 | 4,121 |
| Neuroblastoma | NMB-7 | High | 62.19 | 0.0211 | 2,952 |
| Osteosarcoma | MG-63 (CRL-1427) | Low | 264.3 | 0.2158 | 1,225 |
| Neuroblastoma | SKNBE(2)C | Low | 211.0 | 1.674 | 126 |
| Melanoma | SKMEL-28 (HTB-72) | Low | 1,728 | 7.061 | 245 |
| Osteosarcoma | U2OS (HTB-96) | Low | 2,038 | 19.43 | 105 |
| Ovarian carcinoma | SKOV3 (HTB-77) | Negative | NA | NA | NA |